menu

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Drug Info Rounds

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

close
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. 

    Released July 28, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. 

    Released July 28, 2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/29/20